Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

The agreement is for Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the ...

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

Scientists at Northwestern University have discovered a drug that could offer a new approach to treating life-threatening ...

Among adults with severe asthma, those with healthy weight, overweight, obesity and severe obesity each had improvements in ...

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech's history in terms of operating cash flowsContinued expansion of commercial partnerships for pip ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

The new-generation drug – also known as QGE031 – binds more tightly to IgE than Roche-partnered Xolair (omalizumab), and that suggests it could be more effective as a treatment for CSU, a ...

Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and ...